{"id":3407,"date":"2026-10-15T09:29:48","date_gmt":"2026-10-15T02:29:48","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=3407"},"modified":"2026-10-15T09:37:52","modified_gmt":"2026-10-15T02:37:52","slug":"antibiotic-allergy-risks-in-children-and-barycela-an-advance-in-antibiotic-free-varicella-vaccine-technology","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/antibiotic-allergy-risks-in-children-and-barycela-an-advance-in-antibiotic-free-varicella-vaccine-technology","title":{"rendered":"ANTIBIOTIC ALLERGY RISKS IN CHILDREN AND BARYCELA: AN ADVANCE IN ANTIBIOTIC-FREE VARICELLA VACCINE TECHNOLOGY"},"content":{"rendered":"

Chickenpox (varicella) is an acute infectious disease caused by the Varicella-Zoster virus (VZV). It spreads easily among children through respiratory transmission or contact with fluid from blisters. Common symptoms include fever, fatigue, and itchy blisters. The disease can also lead to complications such as skin infections, pneumonia, encephalitis, meningitis, and shingles later in life<\/span> [6<\/a>]. Given these risks, vaccination is an effective preventive measure against chickenpox.<\/span><\/span><\/p>\n

In recent years, however, many parents have become increasingly concerned about vaccine safety, particularly antibiotics that may remain as trace residues from the manufacturing process and the potential risk of adverse reactions in children with sensitivities. In this context, the introduction of Barycela, a second-generation varicella vaccine based on the MAV\/06 strain and manufactured without antibiotics, represents a new approach to addressing concerns about antibiotic content in vaccines while supporting improvements in vaccine quality and confidence in immunization.<\/span><\/p>\n

1. Risks of antibiotic allergies associated with vaccines<\/strong><\/span><\/p>\n

1.1. Why are antibiotics used in vaccines?<\/strong><\/span><\/p>\n

During the production of many commonly used vaccines, including those against measles, mumps, rubella, and varicella, antibiotics such as neomycin, streptomycin, and erythromycin may be added to cell or virus culture media to limit unwanted bacterial or fungal contamination and maintain aseptic conditions.<\/span> [3<\/a>]<\/span><\/p>\n

After virus cultivation is complete, the vaccine undergoes rigorous purification processes to remove most residual production components. However, small trace amounts of antibiotics may remain in the finished vaccine.<\/span> [8]<\/span><\/p>\n

1.2. Potential adverse reactions to antibiotics in children with sensitivities<\/strong><\/span><\/p>\n

Although the amount of residual antibiotics in vaccines is very low and reactions are rare, these components may still warrant consideration in children with sensitivities or a history of allergies. Possible allergic manifestations following vaccination include hives, skin rashes, itching, irritability, reduced feeding, or disturbed sleep.<\/span><\/p>\n

In infants, these signs may be mistaken for normal physiological responses. If an allergic reaction is not recognized promptly, it can become more severe and, in rare cases, lead to anaphylaxis. Therefore, screening for a history of allergies before vaccination is important. The development of vaccines manufactured without antibiotics is also an approach that can help address concerns about antibiotic-related risks.<\/span><\/p>\n

 <\/p>\n

2. Advancements in Barycela, a second-generation varicella vaccine<\/strong><\/span><\/p>\n

Barycela is a varicella vaccine developed by GC Biopharma (South Korea) using the attenuated MAV\/06 virus strain. By eliminating the use of antibiotics throughout the manufacturing process, Barycela represents a notable advancement in vaccine manufacturing technology.<\/span><\/p>\n

Barycela is a second-generation varicella vaccine developed based on the research and manufacturing experience gained from the first-generation Varicella-GCC vaccine, which has been available in Vietnam since 2008. Building on this foundation, GC Biopharma has introduced several improvements intended to enhance vaccine stability and safety. Key advancements include:<\/span><\/p>\n